Related Experiment Video
Updated: May 11, 2026
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer
Xue-Hui Chen1, Zhi-Qiang Li, Hua Peng
1The First Affiliated Hospital of Xinxiang Medical University, Weihui, People's Republic of China.
Abstract:
One of the most important molecules mediating the proliferation, growth, and metastasis of cancer cells is insulin-like growth factor (IGF), with its receptor IGF-1R. Here, we describe the potential of an IGF-1R monoclonal antibody, HX-1162, on liver cancer apoptosis in vitro and in vivo. We found that HX-1162 could induce the apoptosis of cultured liver cancer cells. Additionally, HX-1162 treatment inhibited the tumor growth after cancer cell grafting and enhanced the cell apoptosis inside the tumor tissue. We conclude that IGF-1R targeting therapy provides a new avenue toward treating liver cancer.
Insights
A novel monoclonal antibody, HX-1162, targeting insulin-like growth factor 1 receptor (IGF-1R), effectively induces liver cancer cell apoptosis and inhibits tumor growth in vitro and in vivo.
Area of Science:
- Oncology
- Molecular Biology
- Immunotherapy
Background:
- Insulin-like growth factor (IGF) and its receptor IGF-1R are critical in cancer cell proliferation, growth, and metastasis.
- Targeting IGF-1R presents a potential therapeutic strategy for various cancers.
Purpose of the Study:
- To evaluate the efficacy of the IGF-1R monoclonal antibody, HX-1162, in inducing apoptosis and inhibiting tumor growth in liver cancer models.
Main Methods:
- In vitro studies on cultured liver cancer cells to assess HX-1162-induced apoptosis.
- In vivo studies involving cancer cell grafting in animal models to evaluate tumor growth inhibition and apoptosis induction by HX-1162.
Main Results:
- HX-1162 demonstrated the ability to induce apoptosis in cultured liver cancer cells.
- Treatment with HX-1162 significantly inhibited tumor growth in vivo.
- Enhanced cancer cell apoptosis was observed within the tumor tissue following HX-1162 treatment.
Conclusions:
- IGF-1R targeting therapy with HX-1162 shows significant potential for treating liver cancer.
- HX-1162 represents a promising therapeutic agent for inducing apoptosis and controlling liver cancer progression.
